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Abstract
CLONING AND EXPRESSION OF PSEUDOMONAS AERUGINOSA ELASTASE
FOR ELUCIDATING THE PATHOPHYSIOLOGICAL EFFECT ON LUNG TISSUE
Derek Draper
Thesis Chair: Ali O. Azghani, Ph.D.
The University of Texas at Tyler
May 2017
Pseudomonas aeruginosa causes acute nosocomial as well as community
acquired pneumonia. In cystic fibrosis patients, this organism causes recurrent infections
and inflammation with a high rate of morbidity and mortality. To support research in
elucidating the molecular mechanisms of Pseudomonas elastase (PE) on disease
progression, PE was expressed in E. coli and the protein purified for further application.
This study represents a valid experimental protocol to produce. Genomic DNA was
isolated from P. aeruginosa and selected regions were amplified using PCR with lasB
gene specification. Amplified DNA was ligated into plasmids and E. coli were
transformed to support the recombinant vector and produce a viable elastase product. The
recombinant DNA was sequenced and accurately matched the pro-Elastase sequence
(1497 bp in length). Purification of enzyme produced via heterologous expression in
ClearColi LPS free E. coli was aided via Ni-NTA Liquid Chromatography system by the
incorporation of a 6x Histidine affinity tag engineered on the C-terminus of elastase.
Analysis by SDS-PAGE revealed a product of ~34 kDa in molecular weight consistent
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with the molecular weight of the naturally produced mature Elastase. Proteolytic activity
was determined via Skim Milk Agar diffusion. Elastolytic activity was determined by
Elastin-Congo Red substrate to be two times the activity of the commercial enzyme.
Cellular anatomy and physiology experiments confirmed the conserved pathologic effects
of the Recombinant Elastase. Immunofluorescent study demonstrated preliminary data
that Recombinant Elastase had the ability to disrupts tight junction structure as evidenced
by fragmentation of ZO-1 proteins in Calu-3 cell monolayers.
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Chapter One
Introduction
Significance and Historical Relevance of Pseudomonas aeruginosa
Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic Gram-negative
bacterium that typically affects hospitalized patients, presents life-threatening responses
in hosts with compromised immune systems, and recurrent infections in patients with
cystic fibrosis (CF) (1, 2). Among other species, P. aeruginosa is normally present in
small numbers in the human intestines and freely living in water and soil. This organism
is termed “opportunistic” because it is normally dealt with by the defenses of the body,
however, when the opportunity arises, as in immunocompromised individuals, it can
cause local or systemic infection (1).
This bacterium was discovered in 1882 by Carle Gessard (2), a chemist and
bacteriologist from France. Dr. Gessard set out to determine why he kept observing blue
and green coloration on the bandages of soldiers. He identified water-soluble pigments
that were derived from the microbe in the pus of infections. These pigments turned bluegreen after exposure to ultra-violet light. He termed this invader Bacillus pyocaneus and
the cause of “blue pus” that was widely observed throughout many infections, especially
in children. This bacterium, now known as Pseudomonas aeruginosa (P. aeruginosa),
possesses the ability to build resistance to most antibiotics making it particularly
dangerous (3, 4, 5, 6, 7). There are numerous cases of infection by P. aeruginosa since its
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discovery in 1882, including an epidemic of diarrhea in the 1940s of 24 new-born infants.
The initial infection was caused by improper sterilization of the milk supply and cleaning
techniques utilized by the hospital staff (7, 8).
In 1928, the first true antibiotic, penicillin, was discovered by Alexander Fleming.
Through his work, he incidentally observed a clearing in petri dishes containing
Staphylococcus where the mold, Penicillium notatum resided. The clearing zones were
caused by the production of an antibiotic by the mold which killed any bacteria nearby.
The United States utilized penicillin in World War II to fight off infection of bacteria in
battle wounds. However, due to its overuse, severely burned patients frequently displayed
P. aeruginosa infections that were typically fatal because of the intrinsic ability of P.
aeruginosa to develop resistance to antibiotics (9). Pseudomonas septicemia had been the
major cause of death after the initial two-day post-burn period. Statistically, this
bacterium is the cause of most fatalities from infection post severe burns (10, 11, 12, 13,
14). In 1954, a study was conducted to determine the epidemiology of this infection
through the hospital and how to potentially contain the pathogen. Infected burns appeared
to be the most important reservoirs. About 3 % of the stools of normal subjects and of
patients with intestinal symptoms carried the organism, which was also isolated from the
nose, throat, nasopharynx, skin and ear of a small proportion of patients and staff in the
burns wards. The hands of the nurses were often contaminated with the bacterium which
would then be spread to various sources through contact (15).
As the knowledge of this bacterium spread and the concurrent use of antibiotics
increased, the relevance of P. aeruginosa amplified. Among the list of infections, corneal
destruction is one of the most commonly observed. After cataract extraction, a ring
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similar in pigment to intra-capsular cataracts is present in many patients. This was
determined to be a pyocyaneous infection (P. aeruginosa) and was treated with
streptomycin therapy because this strain was resistant to penicillin (16). In the cornea, it’s
been observed that P. aeruginosa causes acute ulceration, hyperacute conjunctivitis,
infection and scarring (17, 18, 19, 20).
Because of P. aeruginosa’s prominence in the hospital environment and postsurgical procedures, studies were directed to the cause of infection and initial treatment of
conditions. A major cause for concern has been in pulmonary medicine. In this realm, the
bacterium contaminates inhalant equipment and becomes a chronic inducer for sustained
infections with ulcer of the lung epithelium and hemorrhage sequel (21).
Today’s impact of P. aeruginosa pathogenesis is centered toward patients
suffering from acute and chronic infections accompanied with a life-threatening injury,
compromised immune system, or illness, such as Cystic Fibrosis (CF). Patients with CF
develop chronic infections because the lung epithelium produce thick and sticky mucus
instead of the typical thin and slippery product. This is due to defective chloride channels
that prevent chloride from exiting the cell, in turn water is abnormally retained and the
mucus becomes thick and immotile. The stagnant mucus becomes a breeding ground for
bacteria and fungi. The most prevalent bacterium in patients with CF is P. aeruginosa
which replaces other causative bacteria. There is no cure for CF, but different treatment
options reduce symptoms and extend life expectancy. Many options include: medications
such as antibiotics, chest physical therapy, pulmonary rehabilitation, kalydeco (improves
function of defective channels), and lung transplant. Due to recurrent Pseudomonas
infections and increase in antibiotic usage in CF patients, P. aeruginosa has become more
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pathogenic and resistant to drug treatment and options become limited for patients in later
stages of this disorder (22). Remedies used today to alleviate infection by P. aeruginosa
include antimicrobial combination drug therapy (beta-lactam antibiotic with an
aminoglycoside). The family of beta-lactam antibiotics are broad-spectrum and consist of
penicillin derivatives, cephalosporins, monobactams, and carbapenems. Further, the
aminoglycoside reduces protein synthesis in Gram-negative bacteria. However, the
choice of specific antibiotic depends on the site and extent of the infection and on the
resistance of the present strain (23, 24). Good examples of these therapy interventions
include the use of the Dutch regimen, an intermittent/combination therapy option in
which patients are treated with a parenterally administered combination of a β-lactam
antibiotic with a β-lactamase inhibitor called Piperacillin-tazobactam or the use of TOBI
podhaler that releases a dry powder directly into the respiratory epithelium (25).
Furthermore, Azghani and colleagues published work on the use of liposomal antibodies,
antibodies surrounded by lipids, to increase the effectiveness of antibodies and decrease
the inhibitory effect in the sputum (26).

Cellular and Molecular Pathogenesis of P. aeruginosa Infection
Normally, the bacterium doesn’t take up a large amount of the whole microbiome
in individuals. However, hospitalized patients are at much greater risk for P. aeruginosa
infection and spreading (1, 2, 27). Thus, when the opportunity arises, this bacterium
makes use of the susceptible hosts (1, 28).
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I.

Bacterial Adhesion
A common laboratory reference strain is the P. aeruginosa PAO1, a spontaneous

chloramphenicol-resistant mutant of the original PAO strain (earlier called “P.
aeruginosa strain 1”). PAO1 was isolated in 1954 from a wound in Melbourne, Australia
and provides a genome of reference for one of the most virulent strains isolated from a
patient and is the most commonly studied strain of P. aeruginosa available (29, 30).
The first step in P. aeruginosa adhesion is colonization of altered epithelium.
Once initially adhered, the bacteria begin to expand and divide into mature, stable
colonies. Many studies describe the use of various pili that allow for complete adherence
to host cells. Further, it has been shown the flagella and other bacterial products act in
adhesion as well (31, 32, 33). It was discovered that the flagella and pili are not necessary
for the initial attachment and formation but do increase the probability of resistance
development (34).
P. aeruginosa is known to produce a biofilm as part of the infection process due
to chronic infections. The process of biofilm formation begins with the initial infection to
the surface of tissue, followed by attachment and formation of microcolonies, and lastly
the biofilm maturation. Once a biofilm is matured in formation, it retains the ability of
antimicrobial resistance caused by many chronic and persistent infections (35, 36, 37,
38). The PAO1 strain was utilized in experiments to study the formation of biofilms. A
Green Fluorescent Protein (GFP) tagged PAO1 wild type elucidated the ability of P.
aeruginosa to infect hosts by studying the composition and adherence of the bacterium in
the formation process of mature biofilms (34).
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II.

Virulence Factors of P. aeruginosa
Both cell-associated and extracellular products of P. aeruginosa contribute to its

virulence. Surface structures, including pili and the polysaccharide capsule or glycocalyx,
appear to mediate the initial attachment of P. aeruginosa to its prospective host, thus
permitting colonization (31, 39, 40, 41, 42). Extracellular enzymes such as alkaline
protease, elastase, phospholipase C, and exotoxin A interrupt cellular metabolism,
degrade infected tissues and promote bacterial invasion. When spreading occurs,
systemic disease results, often with fatal consequences (39, 40, 43).
After years of study by pioneers including Morihara et al., Barbara Iglewski and
colleagues, it became apparent that the bacterium's virulence depends on many cellassociated and extracellular factors. An initial break in the skin and mechanical
boundaries can cause an infection by this bacterium because of its repertoire of virulence
factors and host compromised immune systems (44, 45, 46). For instance, in vivo studies
described the use of mutant strains that did not produce exotoxin A, exoenzyme S,
elastase, or alkaline proteases (47, 48). It was discovered that these elements are
necessary for P. aeruginosa infection; however, the anatomical location determines the
ability of any given virulence factor in the infection establishment (47, 48, 49). Various
strains have adapted to antibiotics and therefore, there is an increased demand for
studying antimicrobial resistance, mechanisms of virulence including secreted toxins, and
ability to form biofilms (50, 51, 52).
III.

P. aeruginosa Extracellular Toxins
The most well-known research on extracellular toxins was performed by Justinus

Kerner, a German poet, practicing physician, and medical writer was the first to
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completely and accurately describe the symptoms of botulism and the botulism toxin that
caused the side-effects such as cramps, vomiting, breathing problems, difficulty
swallowing, double vision, and weakness or paralysis. Botulism is caused by the
neurotoxin produced by various strains of the bacterium Clostridium botulinum (53, 54,
55). Kerner went on to describe a therapeutic use of the botulism toxin based on a set of
experiments he performed using the toxin in clinical and animal experiments.
Interestingly, modern developments made by Alan Scott in 1980 have allowed for the
medicinal purpose of these toxins and are some of the most widely used pharmaceuticals
in treating patients with strabismus (crossing eyes), cosmetic applications, abnormal
disorders associated with movement, and even pain (53, 56).
This observation by Kerner was a huge shift in the understanding of disease and
infection by bacteria. No longer were bacteria the exclusive cause, but substances
released by the bacteria were acting in on tissues to allow them to infect, propagate,
survive and thrive. There are two types of toxins that bacteria can express: exotoxins or
endotoxins. Exotoxins are directly secreted by bacteria (54, 55). They cause damage to
tissue of the host by destroying key proteins that maintain tissue structure or cellular
metabolism. Further, these exotoxins can also be released during lysis of the cell. On the
other hand, an endotoxin located in the outer membrane of Gram-negative bacteria, also
known as lipopolysaccharides (LPS), illicit strong responses of inflammation and other
immune responses when exposed to a host (53, 57).
Early observations of P. aeruginosa by Morihara’s lab pointed to the production
of toxins but it wasn’t until the 1970s that these toxins were properly characterized. P.
aeruginosa produces an expanse of extracellular toxins (exotoxins), which include
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phytotoxic factor, pigments, hydrocyanic acid, proteolytic enzymes, and phospholipase
(58, 59). The most important factor in the pathogenicity of P. aeruginosa is the
elaboration of a group of protein exotoxins including Exotoxin A, the first studied
exotoxin by this bacterium. This enzyme enters host cells through receptor-mediated
endocytosis and lands in the cytoplasm where it catalyzes ADP-ribosylation inactivating
Eukaryotic Translation Elongation Factor 2 (eEF-2), a protein necessary for ribosomal
function, leading to a standstill in protein biosynthesis and the host cell’s eventual death
(60, 61, 62). This and the many other exotoxins altogether can produce a variety of
disease symptoms including leukopenia, acidosis, circulatory collapse, necrosis of the
liver, pulmonary edema, hemorrhage, and necrosis of kidneys. The proteolytic enzyme,
P. aeruginosa Elastase, that breaks down peptide bonds of proteins produced by P.
aeruginosa are responsible for the hemorrhagic and necrotic changes in the skin, as well
as devastation of the cornea in eye infections. The hemolytic phospholipase C enzyme
may be responsible for the damage and overall destruction of pulmonary surfactant.
When this occurs, the result is typically atelectasis or the collapse/closing of the lungs
(63). This effect, together with inflammatory response and the necrosis of lung
parenchyma are important in the pathogenesis of the damage to lungs due to
Pseudomonas-induced pneumonia. Further, it has been implicated that various strains of
P. aeruginosa produce an enterotoxin responsible for gastrointestinal diseases (54, 55,
56).
In 1985, Dr. Iglewski’s team employed a genetic approach to determine the
contribution of Exotoxin A, exoenzyme S, Elastase and alkaline protease to the
pathogenesis of P. aeruginosa. They introduced mutations into various strains with
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chemicals or transposons (48). Pathogenesis of the mutants were then identified using
immunological, chemical, or toxicity assays to observe their changes and/or increased
resistance or pathogenesis. Mutants were extensively characterized in vitro to ascertain
that they were identical to their parent strain except for the production of the desired
product that could be utilized for further studies as knockouts, knockdowns, or
dysfunctional for the appropriate exotoxins or enzymes produced. One such model, PAOE64, was a mutant that produced an antigenically identical elastase except for its
deficiency in elastase activity (48, 64). The idea was to better understand how these
various toxins produced by P. aeruginosa acted alone, together, or in synergy. This
comparison of the overall function of this bacterium signified infection is not due to a
single secreted factor alone. As expected, the data indicated that virulence of P.
aeruginosa is multifactorial and the relative contribution of a given strain (mutation) of
P. aeruginosa product may vary with the type of infection and the location of tissue
because of the different cell types and immune responses (44, 64, 65).
Until the 1960s and 70s, the least-characterized, yet most likely major virulence
factor, was the trypsin-sensitive, heat-labile exotoxin, P. aeruginosa Elastase. This toxin
had been shown to be lethal for mice and can elicit hypotensive shock in monkeys and in
dogs after intravenous administration. Previous investigations in the Liu laboratory
showed that Elastase inhibits uridine and amino acid uptake by cultured cells and inhibits
the respiration of mitochondria derived from mouse liver cells (65, 66). The ability of this
metalloprotease to degrade several extracellular proteins including elastin and collagen
and functionally inactivate human immunoglobulin G, serum alpha1-proteinase inhibitor,
and several complement components accentuates its potential importance as a virulence
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factor (67). Because of the emphasis of my thesis research, the remainder of this
introduction focuses on the characterization of Elastase, disruption of tight junctions and
increased epithelial permeability, and the interplay of signal transduction pathways
involving P. aeruginosa Elastase (PE).
IV.

Characterization of P. aeruginosa Elastase
Morihara and his coworkers demonstrated in 1965 that most strains of P.

aeruginosa produce three distinct proteinases and one, a semialkaline proteinase,
possesses elastolytic activity as a single homogenous enzyme (68, 69). In vivo studies
revealed the pathologic effects of purified PE in animal models. Intracutaneous injection
of PE in microgram amounts had the ability to cause hemorrhage, cellular infiltration of
the subcutaneous tissue and muscular layer, and degeneration of endothelial cells (70).
Similar results occurred via intraperitoneal injections in mice causing pulmonary and
subcutaneous hemorrhaging (71). The production of PE is strain specific and
accompanied to taxonomic origin (72). Inhibition of elastase was achieved temporarily
with phosphoramidon, a powerful inhibitor for many proteases and elastases. The
elastolytic effect was inhibited for a period of twelve hours following the addition of the
compound to an elastase solution injected into the eyes of rabbits and subcutaneously into
mice (73, 74).
Further biochemical and molecular studies characterized the specific gene coding
for PE. A DNA fragment from P. aeruginosa was cloned into E. coli via plasmid
transformation. Deletion mutant analysis confirmed the full-length gene coding for
elastase must be approximately between 1.0-1.3 Kb in length (75). The DNA segment
encoding Elastase was cloned and the complete nucleotide sequence was determined in
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1989. The primary structure of Elastase was determined to be like thermolysin produced
by Bacillus thermoproteolyticus because the functionally important amino acid sequences
and residues are identical and both are Zn-metallo proteinases. These proteinases are
found in many microorganisms but also in snake venom and within the organs and tissues
of mammals. Mature elastase is an enzyme containing 301 amino acids with a molecular
mass of 32,926 daltons (33kDa). Further, a “pro” sequence was determined containing
197 amino acids in length. Initially, Elastase is expressed as an inactive pro-peptide
similar to other proteases, and this “pro” domain is cleaved in the periplasmic space to
produce the active Elastase (76, 77, 78). A more in depth molecular characterization of
the Elastase structural gene (lasB) was performed by Iglewski et al. in 1988. The
nucleotide sequence of the lasB gene containing 1,491 base pairs encoded a protein of
498 amino acids with a molecular mass of 53,600 daltons. Using PAO mutants with
inactive elastase, two structural genes (lasA and lasR) were quantified and verified
necessary for the activation of the mature elastase (67, 79, 80, 81). LasR was identified as
a requirement for the transcription of lasB and lasA protein had the ability to enhance the
elastolytic activity of mature PE (81, 82, 83).
Pathophysiological Effect of PE
I.

Electrophysiology and Paracellular Permeability

Normal respiratory epithelium plays a key role in the immune response to
pathogens and as a protective barrier against foreign microorganisms and
macromolecules. During embryogenesis and cell differentiation, layers of epithelium are
specially developed to create a barrier for the body’s defense and integrity. Along with a
barrier function, polarized epithelial cells are key to the exchange of ions and water
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across membranes within the lungs and other tissues (84, 85). However, the normal
release of minute amounts of exotoxins by a bacterium, such as P. aeruginosa, might
cause a breach in this barrier increasing the susceptibility to bacterial invasion and
infection. One in vivo study sought to elucidate this idea and observed the effect of PE on
the lungs of guinea pigs. This demonstrated that aerosols of elastase increased the
clearing rate of labeled albumin. Further, PE was traced to interruptions specifically in
the tight junction structures that help in the creation of a tight monolayer of epithelial
cells (86, 87). Therefore, an increased clearing rate of a substance in the lungs coincides
with a decreased barrier function caused by PE addition.
To help form regulatory barriers, the epithelial cells create intercellular junctions
called tight junctions. Tight junctions are considered the ultimate gateway between the
cells and the underlying tissues. The complexes that form tight junctions are composed of
various proteins including occludin, claudin, and the cytoplasmic scaffolding proteins
zonula occludens (ZO-1, -2, -3) (88, 89, 90). Disruption of the proteins that form the
complexes for tight junctions can cause an adverse effect in the transport and filtering
functionality of the epithelium (91, 92, 93). Therefore, as demonstrated previously, any
alteration by bacterial toxins can interfere with normal barrier functions (94, 95). MadinDarby canine kidney (MDCK) epithelial cells demonstrated the ability of PE to perturb
the function of the tight junctions by altering the concentration of ZO-1 proteins without
membrane disruption. This indicated that PE has a toxic effect on the barrier function of
epithelial monolayers and alters at least one protein in the tight junction complex (96).
Further, virulence factors released from P. aeruginosa including PE and exotoxin A
exhibited an ability to increase epithelial permeability by the measurement of Trans-
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epithelial Electrical Resistance (TER), however, during experiments with acute
pneumonia, data suggested that PE breaks down tight junctions increasing its virulence.
And in synergy with lipopolysaccharide (LPS), PE demonstrated an increase in epithelial
permeability and facilitated the influx of neutrophils causing an inflammatory response
(97, 98, 99, 100).
II.

Molecular Mechanism of the Disruption in Epithelia Integrity
Since PE disrupts the function of tight junctions without resulting in cell injury or

death, investigations to explain this effect were explored. A plausible theory pointed in
the direction of host signaling pathways involved in the formation of tight junctions
because previous research determined the ability of Pseudomonal proteases in stimulating
the extracellular regulated kinase (ERK) signaling pathway, enhancing IL-8 production in
vitro, and activating other inflammatory responses through certain protease-activated
receptors (101, 102, 103). Therefore, an exploration in the role of PE on the pathway of
tight junction formation was studied. It is known that tight junction assembly and sealing,
cellular localization of occludin and ZO-1, along with the previous pathways described,
are in part regulated by protein kinase C (PKC) signaling (104, 105, 106). Our lab
incorporated a study that discovered the impact of PE-induced PKC signaling and the
redistribution of the multifunctional complex that defines tight junctions. The results
demonstrated PE pathogenesis targets occludin, ZO-1 and F-actin by elevating PKC
levels and causing tight junction translocation and cytoskeletal reorganization (107).
These experiments all elucidated the mechanistic action of PE on paracellular
permeability and tight junction disruption. The next discoveries allowed for an enhanced
explanation of this distinct effect on cell signaling.
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III.

Signal Transduction Pathways Involved in Pathogenesis of PE-induced injury
The epidermal growth factor receptor (EGFR) is a complex signaling pathway

involving a number of signaling cascades. This receptor is common to many cell types
including lung epithelium. Receptor tyrosine kinases, like EGFR, are transmembrane
receptors composed of an intracellular domain, extracellular ligand-binding domain, and
a transmembrane portion (108). The EGF family of receptors are initially activated via
ligand-receptor complex formation. It is known that members of this family of tyrosine
receptors are activated by a multitude of ligands including Epidermal growth factor
(EGF), Transforming growth factor (TGF – α), heparin binding (HB)-EGF, amphiregulin,
β-cellulin and epiregulin (109, 110). Once ligand bound, a conformational change occurs
within EGFR, dimerization of the receptors, and then autophosphorylation of the tyrosine
residues results. Transient phosphorylation of tyrosine residues on internal cellular
substrates activates downstream signaling including phospholipase C-y (PLC-y), PKC,
mitogen-activated protein kinases (MAPK), and ras GTPase-activating protein (GAP)
(111). This ultimately leads to increased activity in angiogenesis, cell differentiation,
proliferation, survival, progression of many cancers, and more recently reported
regulation of tight junctions via PKC signaling (104, 105, 106, 112, 113, 114, 115).
A consequence of autophosphorylation of EGFR, as mentioned previously, is the
activation of downstream elements like MAPK. Mitogen-activated protein kinases
include ERK 1/2, ERK 3/4, ERK 5, ERK 7/8, c-Jun N-terminal kinase (JNK) 1/2/3 and
p38 isoforms. It is known that ERK signaling is involved in cell proliferation and through
extracellular transient activation by EGFR, can regulate tight junction protein assembly
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and cytoskeletal rearrangement (116). Our lab demonstrated the ability of PE to activate
the epidermal growth factor receptor and further elicit downstream activation of the ERK
1/2 arm of the MAPK pathway within 5 minutes of apical exposure of Calu-3 cell
monolayers. This activation preceded the disruption in tight junction structure by the loss
of localization of occludin, ZO-1, and cytoskeletal reorganization (Castillo, Azghani,
unpublished). Further, this ability of PE to activate this signaling cascade was revealed
through inflammatory pathways that displayed an enhanced IL-8 production via NF- B
activation (117).
Another family of downstream signaling affected by EGFR activation is the Rho
family of small guanosine triphosphate (GTP) – binding proteins. Rho proteins are
identified to be important in the regulation of tight junction structure, function and
assembly (115). This is important in the context of mediating Rho GTPases because
previous studies of bacterial toxins on tight junction and actin cytoskeleton documented
their ability to reorganize actin cytoskeleton, disrupt tight junction structure and function,
and causing the formation of gaps in cell monolayers (100). This was further illustrated
by additional studies displaying Rho protein importance in tight junction structure and
function regulation (118, 119). Experiments ran in our lab verified a similar effect caused
by PE on cell monolayers. RhoA GTPase was activated through EGFR and MAPK
signaling by PE treatment on cell monolayers and confirmed by morphological analysis
with fluorescent microscopy (Pal, Azhgani, unpublished). However, even with all the
knowledge accrued, there are still questions that need to be answered. Therefore, new
methodology in our lab seeks to make the studies of elucidating the mechanisms more
efficient.
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Goals of this Thesis
•

Synthesize a Recombinant Elastase

•

Measure and compare activity of Recombinant Elastase to commercial product

•

Define pathophysiologic effects of Recombinant Elastase in comparison to
published data on P. aeruginosa Elastase

Synthesizing a Recombinant Elastase
I.

History of Cloning and Recombinant Technology

The process of molecular cloning dates to the late 1960s with the discovery of
restriction endonucleases, better known as restriction enzymes, that possess the ability to
cleave specific regions of DNA. With this molecular machinery, along with reverse
transcriptase and polymerase chain reaction (PCR), recombinant technology expanded
exponentially as techniques improved manipulating the genetic material. The basic
concept in cloning involves (1) the isolation of coding DNA fragments through PCR
amplification, (2) ligation of isolated DNA, termed inserts, into an appropriate plasmid
genetic carrier, (3) transformation of plasmid into a suitable host for propagation, (4)
screening and selecting for hosts containing the intended plasmid, and lastly (5)
expression of recombinant protein in new host organism (120). The process of
manipulating DNA and creating suitable recombinant hosts for expression is straight
forward, however, the selection of primers, vectors, extraction techniques, percent yield,
and activity of recombinant product defines the actual efficiency of any select protocol.
Bever and Iglewski performed the first cloning and expression study of PE in
1988. They utilized a pUC18 plasmid to transform E. coli. The specific E. coli employed
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in this cloning process was the TB1 strain that has an hsdR mutation which allows for
the efficient transformation of unmethylated DNA from PCR amplification. Further,
they implemented an E. coli cell-free transcription-translation system that resulted in
small amounts of gene products. Elastolytic activity was measured by
spectrophotometry readings using Elastin-congo red (ERC) of total cell lysates (80). The
next group of researchers that attempted to clone and express PE utilized an HB101 E.
coli strain with pUC18. This strain displays high stability of recombinant vector, high
efficiency of transformation, and doesn’t require a heat shock step. However, their
representation of recombinant products does not account for purification technique or
possible interaction by lipopolysaccharide (76, 77). More recent developments
attempted the expression in a methylotrophic yeast, Pichia pastoria, which allowed the
researchers to produce high yields of protein with an inexpensive induction promotor,
AOX1, by methanol. Although yeasts produce a high yield of recombinants and are
economically friendly, in comparison to E. coli, yeast are slow growers, protein
production may take days versus hours, they must be produced immediately before use,
and usually many clones need to be screened for protein production before a good
producer is found (121).
An improved cloning technique was presented in 2013 by utilizing a plasmid
containing a 6-consecutive histidine residue tag and transforming E. coli BL21 for
expression (122). The BL21 strain is deficient in Lon protease and OmpT protease and
is therefore generally preferred for recombinant protein expression. Furthermore, this
strain of E. coli contains an RNA polymerase that recognizes the lac promoter necessary
for Isopropyl β-D-1-thiogalactopyranoside (IPTG) induced expression. However, Raftari
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et al. (2013) used a 6x histidine tag for verification via western blot analysis. However,
they state their recombinant product to be 53 kDa in size rather than the 33 kDa product
that should be expected (122).
The improvement of recombinant technology over time has dramatically
increased our potential to create a more economically friendly enzyme, however, more
work is necessary to produce an experimentally useful recombinant product. There are
several concerns not accounted for with the previous research including
lipopolysaccharide (LPS), efficient selection and ability to freeze stocks, easy
purification techniques, correct size and activity of recombinant enzyme, and the ability
to represent identical pathophysiological function to the naturally produced enzyme.
Therefore, our overall goal is to improve the technology to account for these concerns
and prove the existence of an identical recombinant Elastase product.
II.

Purpose of Developing a Recombinant P. aeruginosa Elastase

P. aeruginosa elastase has demonstrated an invalidating ability to cause
detrimental effects to the human body through in vivo signs and symptoms, such as:
edema, fibrosis of the lungs, tight junction disruption, increased paracellular
permeability, and induced inflammatory responses. However, much research remains to
elucidate the molecular mechanisms for the activation of the pathways involved. To
further our laboratory’s research efforts, it was decided to clone and purify PE instead of
purchasing the commercially produced and costly product. The purpose of this thesis is to
offer an alternative process that is cost effective, efficient, and corrects for concerns from
previous cloning techniques. This thesis elaborates on the ability to produce a
recombinant PE that can be utilized for research purposes that further characterize the
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precise nature of the previously studied effects in vitro and in an animal model of
pulmonary infection and inflammation. This provides a laboratory setting that indubitably
becomes self-efficient, an opportunity to reduce funding expenses for further project
goals, and more knowledge in the process of PE production and characterization.
Hypothesis
In this study, evidence is provided in support of the hypothesis that P. aeruginosa
Elastase can efficiently and effectively be cloned and expressed in E. coli. The
significance of this study proves the identity of the recombinant enzyme (RecE) produced
in terms of enzymatic activity and physiologic effects in vitro. The hypothesis was
addressed by DNA isolation from strains of P. aeruginosa that produce PE and cloning
the gene responsible for PE, lasB, with specifically designed primers. Follow up
biochemical analysis and in vitro studies confirmed RecE identity as well as its
pathophysiological activity.

19

Chapter Two
Materials and Methods
1) Bacterial strains:
a) Pseudomonas aeruginosa: The strain of Pseudomonas aeruginosa (P.
aeruginosa) is a clinical strain isolated from a patient positive for cystic
fibrosis disorder (UT Health Northeast, Tyler, TX). For our experiments,
this isolate was sub-cultured into 3 mL of Luria-Bertani (LB) broth at
37°C for 24 hours before DNA isolation.

b) Escherichia coli: Two separate strains of Escherichia coli (E. coli) were
used in this experiment. The first strain, 10G electrocompetent; Lucigen,
Radnor, PA, was used for plasmid amplification and second strain,
ClearColi BL21; Lucigen, Radnor, PA, was utilized for protein
expression. ClearColi is a genetically modified E. coli that contains an
altered form of lipopolysaccharide that does not trigger an endotoxic
response in human host.
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2) Amplification of lasB gene:
a) Bacterial genomic DNA isolation: Ultraclean® Microbial DNA Isolation
Kit (Mo Bio Laboratories, Inc, Carlsbad, CA) was used to isolate bacterial
DNA according to the manufacturer’s protocol. DNA was analyzed for
purity using a Thermoscientific NanoDrop 2000 Spectrophotometer
(ThermoFisher, Waltham, MA) to assess the quality of the isolated DNA.
P. aeruginosa DNA was evaluated by absorbance at 260 nm.

b) Primer Design: Primers used for amplification of the LasB gene (P.
aeruginosa Elastase coding gene) were the Forward LasB and Reverse
LasB primers as follows:
5’>GCGCCCATGGGCAAGAAGGTTTCTACGCTT<3’ (sense primer
containing ATG start codon), containing a NcoI restriction site and
5’>CGCGGGATCCCAACGCGCTCGGGCA<3’ (anti-sense primer),
containing a BamHI restriction site (Eurofins Genomics, Louisville, KY).
The highlighted regions contain the restriction enzyme recognition sites.
These primers were developed by analyzing the beginning and end of the
publicly available gene sequences for LasB on GenBank. The gene was
amplified by Polymerase Chain Reaction (PCR) utilizing the PfuUltra II
Fusion HS DNA Polymerase (Agilent Technology, Santa Clara, CA) in a
Bio-Rad T100 Thermal Cycler (Bio-Rad Laboratories, Hercules, CA).
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PCR specifications were: Heating at 95 C for 5 minutes, Initial
Denaturation at 95 C for 30 seconds, Annealing at 52 C for 30 seconds,
Elongation at 72 C for 5 minutes, and 40 rounds. After amplification, the
product was analyzed using agarose gel electrophoresis and sent for
sequencing to Eurofins Genomics (Louisville, KY) to verify the amplified
gene. The recombinant lasB gene sequence was deposited in the NCBI
GenBank database (accession number KY861927).

3) Transformation of E. coli:
a) Digestion and Ligation with bacterial plasmid: The pET28b plasmid
(Novigen Sciences, Inc, Washington, DC) was utilized for LasB gene
incorporation, which installed the sequence tag containing 6 histidine
residues (6xHis tag) to the C-terminus of Recombinant Elastase (recE)
allowing single column purification by nickel affinity chromatography.
Amplified LasB gene and pET28b vector were digested with NcoI and
BamHI restriction enzymes (New England Biolabs, Ipswich, MA). The
digested LasB gene and pET28b vector were purified using the Qiagen
MinElute Reaction Cleanup Kit (Qiagen, Hilden, Germany). Purified
LasB and pET28b were mixed and ligated with T4 DNA ligase (New
England Biolabs, Ipswich, MA) according to the manufacturer’s
directions. Subsequently, the ligation mixture was transformed into E. coli
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10G electrocompetent cells (Lucigen, Radnor, PA) by electroporation
using an Eppendorf Eporator (ThermoFisher, Waltham, MA). Cells were
grown on an LB agar plate containing kanamycin (50 µg/mL) for selection
of the pET28b plasmid. Colonies were screened for the presence of LasB
via colony PCR and positive hits were subsequently grown up in LB
broth. The DNA was extracted from selected colonies and sent for
sequencing (Eurofins, Louisville, KY). Plasmids with a confirmed
sequence for LasB were transferred into ClearColi (Lucigen, Radnor, PA)
and successive expression experiments were carried out.

b) Inductive Expression of Recombinant Elastase: For expression, 5 mL LB
broth cultures containing kanamycin were inoculated and grown overnight
at 37°C. These cultures were later transferred to 1 L shaker flasks that
were sterilized and made lipopolysaccharide (LPS) free by baking at
350°C for 3-4 hours. We incubated the flasks with shaking at 250 rpm at
37°C. Upon reaching an OD600 between 0.6 – 0.8, cells were induced with
0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Carbosynth, San
Diego, CA) and allowed to incubate overnight at a reduced temperature of
30°C. Cells were harvested by centrifugation (Rotor TA-14-50, Beckman
Coulter, Allegra 25R Centrifuge) and stored at -20°C until purification.
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4) Protein Harvest and Purification:
a) Cell Lysing: Harvested cells were thawed at 4°C and resuspended in Lysis
Buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4). Lysis was carried out
by sonication in a 50 mL conical tube on ice using a Qsonica Sonicator
(Qsonica, LLC, Newtown, CT) with 70% amplitude, a process time of 5
minutes, pulse-on for 1 second, and pulse-off for 2 seconds. After
sonication, the whole-cell lysates were centrifuged (Rotor TA-14-50,
Beckman Coulter, Allegra 25R Centrifuge) at 14,000 rpm for 40 minutes
at 4°C to separate the insoluble cell matter from soluble supernatant
containing our recombinant Elastase (recE).

b) Fast Protein Liquid Chromatography (FPLC): Purification of recE was
performed on a Bio-Rad FPLC NGC Chromatography System (Bio-Rad,
Hercules, CA) the supernatant was applied to a nickel-nitrilotriacetic acid
(Ni-NTA) affinity column pre-equilibrated with Wash Buffer (50 mM
Tris, 300 mM Sodium Chloride, pH 7.5) using a DynaLoop 90 (Bio-Rad,
Hercules, CA). Subsequently, the column was washed with 10 column
volumes of Wash Buffer, then 10 column volumes of low concentration
imidazole buffer (50 MM Tris, 300 mM Sodium Chloride, 25 mM
Imidazole, pH 7.5), to remove non-specifically bound proteins, before
final elution with Elution Buffer (50 MM Tris, 300 mM Sodium Chloride,
250 mM Imidazole, pH 7.5). During the elution process, absorption of
eluent was monitored with Bio-Rad FPLC NGC Chromatography System
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(Bio-Rad, Hercules, CA) and fractions collected with a BioFrac Fraction
Collector (BioRad, Hercules, CA). Fractions showing strong absorption at
280 nm were kept for analysis on a 12% Sodium dodecyl Sulphate
Polyacrylamide Gel Electrophoresis (SDS-PAGE) using a Mini-Protean
electrophoresis apparatus (BioRad, Hercules, CA) to verify the molecular
weight of the purified product expected to contain recE. The recE
containing fractions (~33kDa) were combined and dialyzed 4x with Tris
Buffer (5 mM Tris-HCl, 0.5 mM Calcium Chloride, pH 7.5) for four hours
each time to reduce the imidazole concentration. The dialysis tubing was
45 mm in width, 29 mm in diameter, and contained a molecular weight
cutoff (MWCO) of 3,500 (Sigma-Aldrich, St. Louis, MO). Once dialysis
was complete the recombinant solutions were centrifuged at 13.3 rpm for
10 minutes to remove any precipitated matter (inactive enzyme). Then, the
final concentration of recE per solution (mg/ml) was determined by UVVis absorption with Thermoscientific NanoDrop 2000 Spectrophotometer
(ThermoFisher, Waltham, MA). The Extinction Coefficient ( ) was
calculated by translating the gene sequence to amino acids using an online
DNA Translator (fr33.net) and subsequently using the software program
Protein Calculator v3.4 (C. Putnam, The Scripps Research Institute,
U.S.A.) to determine at A280 Molar Extinction with all disulfides.
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5) Recombinant Elastase Activity Assessment:
a) Proteolytic Activity: Proteolytic activity was assessed by Skim Milk Agar
Diffusion Plate analysis using varying concentrations of recE solution
(7.36U/ml, 3.68U/ml, 1.84U/ml, and 0.74U/ml). Petri-dishes containing
1.5% skim milk powder and 1% agar were used to place round filter
papers loaded with 10 L of recE solution and observed for casein
diffusion every 30 minutes for 4 hours, then overnight.

b) Elastolytic Activity: Elastolytic activity was assessed by Elastin-Congo
Red Assay (ThermoFisher, Waltham, MA) by two separate methods. In
the first method and step, a standard Optical Density (OD) per mg of
elastin using Porcine Pancreatic Elastase (Worthington Biochemical
Corporation, Lakewood, NJ) was developed to compare our recE for
activity. Varying concentrations of elastin substrate (0, 2, 4, 6, 8, and 10
mg/ml) were added to 1 mL eppendorf tubes with constant volumes of
Porcine Pancreatic Elastase (50 L/ml) and left on a shaker for 1 hour at
37°C. OD was determined by spectrophotometry at A485 using the BioRad SmartSpec Plus spectrophotometer (BioRad, Hercules, CA) and the
average OD per mg substrate was calculated (+/- 5%). In step two, we ran
an activity assay for our recE unknown by keeping the concentration of
enzyme constant (50 L/ml mixture) and increasing amounts of the elastin
substrate (0, 2, 4, 6, 8, 10 mg). This elastolytic assay ran on a shaker for 1
hour at 37°C before reading OD. An OD per mg RecE was calculated to
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determine if enzyme displayed a linear increase in solubilization with
increasing substrate. To determine the mg of substrate solubilized, the OD
readout was subsequently divided by the standard OD per mg substrate
previously determined in the first step. Then, the units of activity per mg
of recE was calculated by dividing the mg of substrate solubilized by the
mg of recE used. One unit of activity equals the mg of elastin solubilized
in 1 hour at 37°C. Equation 1 below demonstrates the previously
mentioned calculations.

Equation 1:
Units/mg = mg Substrate Solubilized/ mg Elastase = (OD Observed)/(OD/mg Substrate)

The second method to analyze elastolytic activity utilized the same
methodology listed above except for being read at 495 nm for absorbance.
Following OD readouts, specific activity was determined by dividing the
activity of the recombinant elastases by the activity of the commercial
elastase and subsequently multiplying by 100 to represent a percentage.

6) Virulence activity of RecE in vitro:
a) Cell Culture: A human bronchial adenocarcinoma epithelial cell-line
(Calu-3, ATCC; Manassas, Virginia) was used as an in vitro model to
study the physiological effects of RecE. The cells were cultured and
maintained in Dulbecco's Modified Eagle's Medium (Gibco, Life
Technologies, Grand Island, New York) at 37°C in a humidified
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atmosphere of 5% CO2 / air. The medium was supplemented with 10%
Fetal Bovine Serum (FBS; Atlanta Biologicals, Lawrenceville, GA), 1%
L-glutamine (Cellgro, Herndon, VA) and an antibiotic mixture of 10%
Penicillin (100 g /ml). Cells were maintained in tissue culture flasks
(Corning, Corning, NY) and were discarded after being passaged 20 times.
The medium for the flasks was changed every other day to avoid nutrient
depletion. Trypsin/EDTA (0.25%, Gibco, Life Technologies, Grand
Island, NY) was used to transfer the cells from flasks to the appropriate
cell culture ware according to the experimental design.

b) Impact on Cell Morphology: To identify morphological changes in
response to concentration and time of treatment with RecE, 24-well cell
culture cluster plates (Costar, Corning, NY) were seeded at 1x105 cells
with Calu-3 cells and grown to confluency before experimentation. Cells
were serum-starved overnight (12 hours) before subsequent treatment with
varying concentrations of RecE (1-8 U/ml) and observed using a Nikon
TMS Inverted Microscope (Nikon, Tokyo, Japan) every 15 minutes for 2
hours. Images were captured using 8 MP, f/2.2, 29mm, phase detection
autofocus Apple camera at 200x total magnification (Cupertino, CA).

c) Immunofluorescence microscopy: Fluorescence microscopy was employed
to investigate the subcellular distribution of target tight junction proteins
in Calu-3 cells during Recombinant Elastase exposure. Calu-3 cells were
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seeded into Lab-Tek Chamber Slides an 8 Well Permanox system
(ThermoFisher, Waltham, MA) at 1x105 cells per chamber. Cells were
treated with 1-2 U/ml of RecE for up to 90 minutes and a control (Carrier
MEM alone) for 90 minutes. Following treatment, cells were washed with
Phosphate Buffered Saline (PBS) 2x and fixed with 4% fresh
paraformaldehyde solution in PBS for 10 minutes at room temperature.
After an additional 2x wash with PBS, cells were permeabilized with 0.1%
Triton X-100 in PBS for 5 minutes at room temperature. The cells were
washed 2x with PBS before being blocked with 1% bovine serum albumin
(BSA) for 1 hour at room temperature. After blocking, the monolayers
were incubated with FITC conjugated Mouse Monoclonal Antibody
against ZO-1 (10 g/ml; Invitrogen, Carlsbad, CA) at room temperature for
60 minutes in the dark. The monolayers were washed 2x with PBS before
the addition of secondary antibody (Goat anti-Mouse IgG) conjugated
with Alexa Fluor 488 (10 g/ml; ThermoFisher, Waltham, MA) at room
temperature for 60 minutes in the dark. The monolayers were then washed
2x with PBS and then mounted using ProLong Gold antifade
(ThermoFisher, Waltham, MA) before microscopic observation. The
monolayers were examined under Zeiss LSM 5 Pascal Laser scanning
Confocal Microscope equipped with an Axiocam HRc Color Digital
Camera (One Zeiss Drive, Thornwood, NY). Photomicrography was
performed under 500x total magnification with oil and images were
captured for visualization in LSM software by Zeiss. Differences in the
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localization of tight junction protein, Z0-1, were visually observed and
documented.

30

Chapter Three
Results
Cloning and Sequence Analysis of Recombinant Elastase Gene from P. aeruginosa
The coding gene for P. aeruginosa Elastase (lasB) was amplified from the
genomic DNA of two separate strains of P. aeruginosa, a clinical strain (from our clinical
isolates collection from CF patients) and PAO1 from ATCC. It is reported that some
strains of P. aeruginosa do not produce elastase, therefore, two strains were utilized to
confirm for the elastase gene contained in the genome. An Ultraclean® Microbial DNA
Isolation Kit (Mo Bio Laboratories, Inc, Carlsbad, CA) was used to isolate the genomic
DNA. Purified DNA was verified by NanoDrop for quality and respective absorbance
was read at 260 nm. Forward and reverse primers were designed based on the nucleotide
sequence coding elastase from P. aeruginosa reported in GenBank Accession no.
M194721 followed by amplification. Figure 1 demonstrates the amplification
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products of the two strains of P. aeruginosa. The amplified product following PCR was

Figure 1: Agarose gel electrophoresis displaying PCR amplification of the lasB gene:
The amplified DNA sequences from Clinical and Laboratory strains PAO1 of
Pseudomonas aeruginosa displayed a PCR product approximately the size of native
elastase gene (1,491 bp).

comparable to the reported size of the lasB gene of 1,491 base pair.
The Clinical strain displayed a higher amplification product and was thus the only
strain used in the rest of the experimentation. After amplification of the lasB gene, a
process of digestion and ligation was performed to insert the newly synthesized PCR
product into the pET28b plasmid. Initially the amplification product from Fig. 1 would
not properly ligate into the pET28b plasmid vector until the required conditions of
ligation and digestion were optimized. Ligation reaction was used to transform an initial
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electrocompetent cell line of E. coli known as 10G Electrocompetent cells. Integration of
plasmid provided kanamycin resistance that allow for screening for incorporation within
cells. Figure 2 demonstrates the correct band size (~1,500 bp) for the lasB gene, from
colony 28, in lane 5 following colony PCR of randomly selected 10G Electrocompetent
cells expressing kanamycin resistance.

Figure 2: Recombinant lasB gene expression in Electrocompetent cells: Agarose gel
electrophoresis after ligation and transformation into 10G Electrocompetent cells and
colony PCR. Lane 1 is the Molecular Weight Ladder, Lanes 2-4 were not clones, and
Lane 5 shows the proper length of the lasB recombinant gene at approximately 1491
bp.
Each well was loaded with 10 l of sample (S1 – S5) or molecular weight
markers and gel ran for 45 minutes before visualization. Several of the colonies present
on the plates were resistant to kanamycin but did not contain the recombinant gene as
visible in the gel electrophoresis in lanes 1-4 of Fig. 2. After gel electrophoresis of our
recombinant gene confirmed the size, colonies were grown up, DNA extracted, and sent
for sequence confirmation through Eurofins in the forward and reverse direction. Figure 3
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displays the result we received after splicing the gene sequences together from the
forward and reverse runs.

Figure 3: Sequence results of the recombinant lasB gene match lasB in GenBank: The
above sequence is the resulting sequence obtained from Eurofins. Vertical line:
beginning and end of gene; Green font: start codon; Purple font: base changes. The
obtained 1557 bp recombinant nucleotide sequence contained homology with lasB
from P. aeruginosa PAO1 (GenBank Accession no. M194721).
The entire sequence return was 1,557 nucleotides in length and a 1,497 base-pair
product was obtained after removing the histidine residue sequences and the bases coding
for thrombin (for removal of tag) located immediately in between the end of the sequence
and the histidine tag. This product corresponds directly to the product size on a previous
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study attempting to clone lasB into Picha pastoris GenBank Accession no. EU265777.
The start codon is highlighted in green and the vertical lines mark the beginning and end
of the lasB gene displayed in Fig 3. Compared with the other elastase gene sequences
reported in GenBank, the nucleotide sequence of the cloned DNA shares 99% homology
with lasB from P. aeruginosa PAO1 (GenBank Accession no. M19472.1) (Figure 3).
Only four bases changed (336 C

T, 1029 T C, 1110 A T, 1122 C

T) were observed

as highlighted in purple of Fig 3. Regardless, when translated, there was no difference
between deduced amino acid sequence and native elastase from P. aeruginosa.
Figure 4 displays the resulting amino acid sequence from our gene sequencing
data.

Figure 4: Complete amino acid sequence of recombinant lasB gene containing the 6x
His-tag: The amino acid sequence was translated from the coding strand of the RNA
template of the recombinant lasB gene. The sequence contains identity comparable to
the naturally produced elastase and contains 6 histidine residues at the end for our
purification tag (blue font).
The importance of translating the code to amino acids is to present the presence of 6
concurring histidine residues that served as a tag when we purified through the Ni-NTA
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liquid chromatography system. Our recombinant gene displays the histidine residues,
highlighted in blue, necessary for this step.
Expression of Recombinant Elastase in ClearColi
DNA was extracted from the 10G Electrocompetent cells and subsequently
introduced into our expression vector ClearColi. Post induction with IPTG, ClearColi
were incubated overnight at a reduced temperature of 30°C before cell harvest. We
utilized this induction condition to optimize the production efficiency. Under these
conditions, ClearColi expressed about 1.083 mg recE/L of cells.
After the expression incubation on the shaker, the cells were subsequently
harvested by sonication and recombinant products separated from the cell debris by
centrifugation. The supernatant was harvested and through a process of Ni-NTA liquid
chromatography, our recombinant elastase was collected and purified as detailed in
methods. The different methods were utilized for protein purification. The initial batch of
recombinant elastase used a standard chromatography column with Ni-NTA liquid
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chromatography and fractions were collected manually as depicted in Figure 5.

Figure 5: SDS-PAGE analysis of fractions from Ni-NTA chromatography of
recombinant elastase: The gel displays the correct size of elastase (34 kDa) and proelastase (55 kDa) with various smaller fragments (~17 kDa).
Ten l of each collected fraction was added to the SDS-PAGE wells in Fig. 5 and are in
order from first collected eluent to last. As expected, lanes 3 through 6 contained the
highest concentration (mg/ml) of recombinant proteins displaying correct size (~34 kDa).
The second (RecE2) and third (RecE3) batch of recombinant elastase were
purified using a fast protein liquid chromatography system (FPLC). The fractions were
automatically analyzed and collected during the elution process. Only fractions
containing the recombinant elastase displaying proper absorbance (280 nm) were
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combined, dialyzed, and finally centrifuged to remove precipitates/impurities.

Figure 6: SDS-PAGE analysis of recombinant elastase post removal of precipitates:
Lane 1 is the Molecular Weight Ladder, Lanes 2 and 3 contain the recombinant protein,
and Lane 4 contains the commercially available Pseudomonas Elastase (34 kDa).
In Figure 6, a confirmation test was performed to assess and compare the size of our
recombinant elastase to that of the commercially available one. The observed size (34
kDa) validates both recombinant elastase batches match that of the naturally produced
and commercially available elastase. According to the SDS-PAGE analysis, the
recombinants and commercial produce banding at 34 kDa. The extinction coefficient for
RecE (ε, λ 280 nm) was 60,690 M-1cm-1 or 1.0937 (mg/ml)-1 cm-1.
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Enzymatic Activity of the Recombinant Elastase
We employed two different biochemical methods to confirm the proteolytic as
well as the elastolytic activity of the RecE product. Skim milk agar plates were designed
with round filters saturated with four different concentrations of RecE as labeled in
Figure 7. This test was used to identify the ability of RecE to proteolytically cleave casein
contained in the skim milk plates. As observed in Fig 7, RecE contains high proteolytic
activity.

Figure 7: Proteolytic activity of the Recombinant Elastase in Skim milk agar
diffusion plates: The plate displayed clearing zones around filter papers loaded with
10 l of varying concentrations of RecE as indicated. Image A shows the ability of
RecE to degrade casein at 5 minutes and after 24 hours (Image B).
The units of activity were then assessed using Elastin-Congo red as the substrate
and subsequently calculated for Fig 8. The round filters (1-4) contained 1083.0, 541.50,
270.75, 135.37 g/ml respectively. As presented in Fig 7A, RecE proteolytic activity was
observed as hydrolysis areas, or transparent zones, within 5 minutes of the addition to the
round filters. This was monitored every thirty minutes for a total of four hours and then
imaged again at 24 hours post addition (Fig. 7B). The clearing zones were evidence of
the ability of RecE to degrade the casein within the skim milk agar plates.

39

Once proteolytic activity was determined, the ability of the recombinant enzyme
to degrade elastin was verified by Elastin-Congo Red (ERC) substrate assay. To test this,
a standard curve was constructed and used to determine the Optical Density (OD) per mg
of substrate solubilized in an hour at 37°C. With this knowledge, the amount of substrate
solubilized by our recombinant elastase was calculated by adding known concentrations
of substrate and RecE and then comparing the observed OD to the standard.
Elastolytic activity (in units) was determined by combining 50 l of RecE and 10
mg of ERC substrate in 1 ml reactions. As a control and comparison, the commercially
obtained elastase produced by P. aeruginosa was included in the protocol recommended
by the manufacturer. The substrate solubilized for each reaction was determined by
dividing the observed OD by the previously determined standard OD/mg substrate. From
this value, the units of activity per mg of elastase (Units/mg elastase) was determined by
dividing the mg substrate solubilized by the mg of elastase utilized. Table 1 compares the
activity of the two recombinant elastases in comparison to the commercial. This
experiment was performed in triplicate and the results presented as the means +/standard deviation.

Table 1: Units of activity for RecE in comparison to commercial elastase: Both batches
of RecE (RecE2 and RecE3) present increased activity in comparison to the commercial
PE. Asterisks represent significant values from commercial.
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Specific activity was determined by dividing the activity of the recombinant elastases by
the activity of the commercial elastase. Specific activity is defined as the change in
optical density (OD) at A485 per hour/mg of elastase written as a percentage in
comparison to the commercial. As represented, we discovered RecE had a significant
increase in activity in comparison to the naturally produced as evident by significant p
values of student’s t-test (p<0.05) for both batches.
In previous studies, elastolytic activity was determined at A495 rather than A485.
We utilized this same strategy to compare our product to previous research on cloning
elastase. As Table 2 depicts, the specific activity of our RecE in comparison to our
commercial is about a two-fold increase.

Table 2: Recombinant Elastase (RecE2 and RecE3) presents increased activity in
comparison to the commercial Pseudomonas Elastase. Asterisks represent significant
values from commercial.
This experiment was performed by using a constant known concentration of elastase
(recombinant or commercial) and 10 mg of ERC substrate. The reactions were left on a
shaker for 1 hour at 37°C before being placed in ice and subsequent absorbance read by
spectrophotometer. The experiment was performed in triplicate and the results presented
as an average of the three trials. Specific activity is defined as the change in optical
density (OD) at 485 nm/hour/mg of elastase written as a percentage in comparison to the
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commercial. Significant increases were determined using student t-test’s comparing the
specific activity of the commercial to the recombinants +/- standard deviation (p<0.05).
Activity was further characterized by demonstrating the ability of RecE to digest
Elastin-Congo red substrate in a linear fashion. Reaction mixtures containing constant
concentration of recombinant elastase and increasing values of substrate were combined.
The OD was read at A485 after 1 hour at 37°C. Figure 8 depicts both recombinant batches
having a linear relationship between the OD/mg elastase and the mg of substrate present
in the reactions.

Figure 8: RecE demonstrates substrate linearity: A linear projection line with respective
slopes and R2 values indicate a linear relationship between the OD readout and ElastinCongo red substrate added.
A trend line was fit to the data showing a linear forecast if substrate is increased. R 2
values were calculated and this determined our lines represent a predictive model for
activity (RecE2, 0.95; RecE3, 0.97).
Virulence activity of RecE in vitro
The purpose of performing the following experiments was to demonstrate the
ability of our RecE to function identically to the commercial elastase in vitro. Calu-3
monolayers were treated with various concentrations of Recombinant Elastase (1-8U/ml).
These units of activity values reflect those of previous experiments in our lab. Figure 9
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demonstrates the time course ability of a concentration at 2U/ml of Recombinant Elastase
to make subtle morphological changes to Calu-3 cell anatomy in 2 hours.

Figure 9: Time Course Analysis of the Effect of Recombinant Elastase on cell
monolayers: Calu-3 cell monolayers were treated with 2 U/ml (a physiologic
concentration) of RecE and images captured at 15 minute intervals for 2 hours (200x
total magnification). Sublet morphology alterations were apparent after 60 minutes.
Cell detachment was minimally observed at 120 minutes.
Monolayers were observed and images captured in 15 minute intervals for 2 hours.
Figure 9 details that an in vitro examination of Recombinant Elastase displays similar
physiological changes at low activity concentrations to the commercial Elastase. Figure
10 demonstrates the concentration effect of a RecE on the cell anatomy and monolayer.
In comparison to 2U/ml, this higher concentration shows substantial morphological
changes and cell detachment at 60 minutes and complete disruption by 2 hours.
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Figure 10: Dose Response Analysis of RecE Effect on cell monolayers: Calu-3 cell
monolayers were treated with 8 U/ml of RecE and images captured at 15 minute
intervals for 2 hours (200x total magnification). Morphological changes and cell
detachment were apparent within 30 minutes.
Molecular Alterations in Tight Junction
We chose 1 or 2 U/ml of RecE activity for Immunofluorescent observations of tight
junction protein, ZO-1, localization. ZO-1 is one of the proteins contained in the tight
junction complex of cell monolayers. Therefore, normal expression of this protein is on
the periphery of the cells to function as a barrier between the basal and apical surfaces.
Immunofluorescent (IF) analysis of ZO-1, a tight junction complex protein,
localization was performed on Calu-3 cell monolayers in chamber slides. The cellular
architecture was studied under immunofluorescent microscopy to look for changes after
treatment with 1 or 2U/ml of Recombinant Elastase-2. Figure 12 displays the localization
effect of treatment with Recombinant Elastase on ZO-1 (630X total magnification).
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Figure 11: Immunofluorescence of Tight Junction Protein, ZO-1, localization after RecE
treatment: Calu-3 cell monolayers were treated with RecE and images captured (630X
total magnification). According to analysis, ZO-1 localization is time and dose
dependent.
As presented by the IF results, the control displayed a uniformly distributed ZO-1 protein
in cell peripheries. In treated cells, however, the continuous ring of ZO-1 was replaced by
punctuate structures indicating degradation or relocation of the proteins. Therefore, ZO-1
organization is both a time-and dose-dependent effect of Recombinant Elastase treatment.
These results complement the data reported in the lab’s earlier research utilizing the
commercial Elastase (107).
In conclusion, a Recombinant Elastase was cloned and expressed that properly
reflects the size and enzymatic activity of the commercially available product from P.
aeruginosa. The ability of RecE to cause anatomical changes in vitro via morphological
and immunofluorescent analysis was characterized. Together, these results demonstrate
45

the ability to utilize the above protocol to produce and efficiently create a recombinant
enzyme for further studying the pathophysiologic effects of P. aeruginosa elastase.
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Chapter Four
Discussion
In this thesis, the goal to synthesize a Recombinant Elastase that is comparable to
the commercially available elastase produced by P. aeruginosa was successfully
accomplished. A recombinant lasB gene was cloned, inserted into pET28b plasmid,
transformed electrocompetent recombinant expression E. coli, and purified a
recombinant, active enzyme. Herein, this discussion describes the key points throughout
the cloning process, improvements, and future research extensions.
Initially, it was planned to utilize two strains of P. aeruginosa during the cloning
process. However, only the clinical isolate following amplification via PCR as the lasB
gene of this strain had more amplification as assessed by the gel electrophoresis (Fig 1).
This strain was isolated from patients with chronic infections of P. aeruginosa and likely
contains an increased resistance to antibiotics. Furthermore, after sequencing the
recombinant lasB gene sequence, the final product contained four base-pair changes in
comparison to the listed sequence on GenBank. This comparison of the gene sequences
suggests that the difference in nucleotide sequence may be attributed to strain diversity
which can also account for increased virulence (122).
An IPTG lac operon promoter system was utilized for expression of the RecE
protein. IPTG is a biological reagent that mimics allolactose in triggering the
transcription of the lac operon. The first improvement in the cloning process involved the
chosen plasmid, pET28b, which contains the lac operon along with nucleotides coding
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for a 6x histidine tag. This improvement allowed for a Ni-NTA liquid chromatography
system containing resin with a high affinity for histidine residues to successfully purify
the RecE with high efficiency as detailed in Figs 5 and 6. Further, the induction process
was enhanced, which improved the gene expression level by manipulating the
temperature from the standard 37ºC to 30ºC to improve the low expression in the first
few trials. In this case, the bacteria might be overwhelmed by production of the enzyme.
Published research indicates the host strain does not prefer recombinant expression of
proteases, therefore, potentially causing inclusion bodies to develop (123). Thus, to
alleviate the stress mechanism caused by the overexpression of cloned genes in E. coli, an
altered growth condition was performed during gene expression to improve the negative
host response. Subsequently, modification in temperature increased the production of
RecE and allowed for effective synthesis of a recombinant product.
Another challenge was the contaminating proteins that were observed at the high
(55 kDa) and low (~17 kDa) banding presented in Fig 5. Pseudomonas produces the
enzyme elastase as a pro-form protein of 55 kDa before being cleaved and subsequently
activated upon release as a mature 33 kDa elastase, with loss of a 22 kDa fragment. The
observed banding support the presence of pro-form elastase and fragments from its
cleavage to produce the mature elastase. To improve production of mature elastase, lower
temperature expression was performed and the protein was purified by Ni-affinity
chromatography. Subsequent centrifugation to remove precipitates that formed after
overnight storage of Ni-affinity purified protein produced RecE representing a clean,
finished product, as judged by SDS-PAGE (Fig 6). These results suggest that the source
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of the contamination stemmed from either degradation of the RecE, proenzyme, and
potentially recombinant enzyme that was no longer enzymatically active.
The activity of the RecE was assessed to determine if RecE retained the published
properties of the commercial enzyme. Using Skim milk agar diffusion plates and an
Elastin-Congo red substrate assay the proteolytic and elastolytic activities of the
recombinant enzyme was validated. The plates containing skim milk displayed clearing
zones proving that the RecE can degrade casein as a proteolytic enzyme. From the
Elastin-Congo red assay assessment, the RecE demonstrated an ability to degrade elastin.
Astoundingly, RecE displayed an increased elastolytic ability in comparison to the
commercial enzyme. This is important because enhanced activity can allow investigators
to use less of the enzyme when studying its effects on lung tissue.
The elastolytic activity confirms the biochemical property of the RecE enzyme.
Therefore, an assessment of whether RecE manipulated cell anatomy in a time and dosedependent manner was examined. Microscopic evaluation of the cultured cells
demonstrated that the RecE’s alters the cell morphology in a dose and time dependent
manner (Fig 9 and 10). The Azghani lab has shown that minute amounts of Pseudomonas
Elastase are produced in vivo and this small amount minimally alters the lung epithelium
(86, 98). As such, this subtle change in the host cell morphology by a physiologic
concentration of RecE mimics previous findings. Therefore, morphological analysis
helped determine the time and dose of RecE to properly emulate the natural observation
in patients for the next examination using immunofluorescent studies.
Pseudomonas elastase has demonstrated an ability to alter the tight junction
complex by manipulation of the ZO-1 protein (107). Through immunofluorescent
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analysis using cell culture slides, the ability of RecE to manipulate the tight junction
complex through ZO-1 reorganization or disruption was preliminarily verified (Fig 11).
This validates previous studies from the Azghani lab that observed the same effect with
the commercial elastase. In normal cell monolayers, the tight junctions are located
uniformly on the periphery. However, with the addition of RecE, the ZO-1 protein is
fragmented in its expression. Future studies should evaluate the manipulation of cell
monolayers by RecE with Trans-epithelial Electrical Resistance (TER) analysis to
confirm the immunofluorescent data presented in this project. In vivo studies will confirm
the impact of RecE –induced alterations in tight junction complex in pathologic
conditions including pulmonary edema.
In summary, the goals of this thesis were successfully achieved by completing the
project on recombinant enzyme synthesis and extensively evaluating the activity of the
RecE. The preliminary data reported here is only the beginning of using RecE to
elucidate the pathophysiological effect on lung tissue. This product can effectively be
utilized in the Azghani laboratory and potentially made into a commercial product for
other labs to use in their respective research. The next step in this line of research will be
examining the effect of RecE on paracellular permeability through Trans-epithelial
Electrical Resistance (TER) and biochemical analysis, such as, western blot for ZO-1.
Earlier research in the lab determined that treatment with elastase from P. aeruginosa
transiently causes the activation of the Epidermal Growth Factor Receptor (EGFR)
resulting in downstream physiologic effects such as inflammation and edema (99, 107).
The exact mechanism for the activation of the EGFR receptor by PE is still unknown and
therefore, RecE can be used to elucidate whether the activation is direct through
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attachment or an indirect fashion through potential cleaving of extracellular pro-ligands.
This will allow for alternative therapy options to be developed to either inhibit the
activation of EGFR and/or potentially using monoclonal antibodies to neutralize
Pseudomonas Elastase (99). The ultimate goal is to develop a method to better treat
patients suffering from infections by this bacterium and hopefully this finding provides
an opportunity for the Azghani laboratory and others to more efficiently study the
pathogenesis of lung injury by P. aeruginosa elastase.
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